Chronic Pain News and Research

RSS

PRIUM creates Centers with Standards database for payer-clients

PRIUM, a medical intervention company that helps reduce the inappropriate use of prescription drugs on workers' compensation claims, wants to highlight good functional restoration clinics and chronic pain management clinics for its payer-clients.

20 May 2013

Non-invasive brain stimulation techniques improve memory

Non-invasive brain stimulation techniques aimed at mental and neurological conditions include transcranial magnetic stimulation for depression, and transcranial direct current (electrical) stimulation, shown to improve memory.

20 May 2013

AbilTo completes Series A financing to expand proprietary programs and technology platform

AbilTo, Inc., a company that delivers proven behavioral health programs to help adults overcome mild and moderate depression associated with major medical events, announced today the completion of a $3 million round of Series A financing to fund the expansion of the Company's proprietary programs and technology platform.

14 May 2013

Experts to give advice and guidance on managing pain among older adults

Older adults living with chronic pain, as well as their families and carers, have the opportunity to give their views to health experts at the University of Greenwich.

14 May 2013

Research: Patients with chronic pain should be evaluated for anxiety disorders

Patients coping with chronic pain should also be evaluated for anxiety disorders, according to new research published in General Hospital Psychiatry.

13 May 2013

NINDS Director affirms NIH's committed to support pain research at APS meeting

In her keynote address to the 32nd American Pain Society Annual Scientific Conference, Story Landis, PhD, director of the National Institute for Neurological Disorders and Stroke, told the APS audience that NIH is committed to research to improve understanding of the biological basis of pain and the development of effective treatments.

10 May 2013

American Pain Society to host Annual Scientific Meeting in New Orleans from May 8 to 11

The 32ed Annual Scientific Meeting of the American Pain Society will convene May 8-11 at the New Orleans Convention Center.

7 May 2013

Researchers publish new Canadian guidelines for diagnosis and treatment of fibromyalgia

Physicians from the McGill University Health Centre (MUHC) and the University of Calgary have published a review article in the CMAJ (Canadian Medical Association Journal) to help family doctors diagnose and treat fibromyalgia.

7 May 2013

Discovery may lead to new treatment for neurodevelopmental, neurodegenerative disorders

A key type of human brain cell developed in the laboratory grows seamlessly when transplanted into the brains of mice, UC San Francisco researchers have discovered, raising hope that these cells might one day be used to treat people with Parkinson's disease, epilepsy, and possibly even Alzheimer's disease, as well as and complications of spinal cord injury such as chronic pain and spasticity.

5 May 2013

Researchers identify genetic risk factor for persistent pain after traumatic events

A new study led by University of North Carolina School of Medicine researchers is the first to identify a genetic risk factor for persistent pain after traumatic events such as motor vehicle collision and sexual assault.

3 May 2013

Schizophrenia cardiovascular risk under-recognized in primary care

UK researchers have found that despite being a major contributor to premature deaths among patients with schizophrenia, cardiovascular disease is less likely to be recorded on their primary care records than those of people without schizophrenia.

30 Apr 2013

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

29 Apr 2013

Maryland professor to receive Pharmacy Educator Award for outstanding achievements in pharmacy education

The American Association of Colleges of Pharmacy (AACP) will honor Mary Lynn McPherson, PharmD, BCPS, CPE, professor and vice chair for academic affairs in the Department of Pharmacy Practice and Science at the University of Maryland School of Pharmacy, for her excellence as a teacher, her outstanding achievements as a researcher and scholar, and her overall impact on pharmacy education and the profession.

25 Apr 2013

Schizophrenia cardiovascular risk under-recognized in primary care

25 Apr 2013

MOPHSF, UW Medicine Division of Pain Medicine team up to improve care for veterans

The Military Order of the Purple Heart Service Foundation and the UW Medicine Division of Pain Medicine are joining forces to assist veterans with treatment for Post-Traumatic Stress, Traumatic Brain Injury, and acute and chronic pain.

25 Apr 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.

24 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.

22 Apr 2013

Neura Therapeutik plans to speed up development of abuse-deterrent, generic extended-release opioids

Neura Therapeutik announced today that they will be accelerating the development of their abuse-deterrent brand and generic extended-release opioids.

19 Apr 2013

Chronic Pain News and Research

PRIUM creates Centers with Standards database for payer-clients

Non-invasive brain stimulation techniques improve memory

AbilTo completes Series A financing to expand proprietary programs and technology platform

Experts to give advice and guidance on managing pain among older adults

Research: Patients with chronic pain should be evaluated for anxiety disorders

NINDS Director affirms NIH's committed to support pain research at APS meeting

American Pain Society to host Annual Scientific Meeting in New Orleans from May 8 to 11

Researchers publish new Canadian guidelines for diagnosis and treatment of fibromyalgia

Discovery may lead to new treatment for neurodevelopmental, neurodegenerative disorders

Researchers identify genetic risk factor for persistent pain after traumatic events

Schizophrenia cardiovascular risk under-recognized in primary care

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Maryland professor to receive Pharmacy Educator Award for outstanding achievements in pharmacy education

Schizophrenia cardiovascular risk under-recognized in primary care

MOPHSF, UW Medicine Division of Pain Medicine team up to improve care for veterans

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Neura Therapeutik plans to speed up development of abuse-deterrent, generic extended-release opioids

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News